<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914290</url>
  </required_header>
  <id_info>
    <org_study_id>IPX056-B09-01</org_study_id>
    <nct_id>NCT00914290</nct_id>
  </id_info>
  <brief_title>A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis</brief_title>
  <official_title>A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMPAX Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMPAX Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation
      of symptoms of spasticity associated with multiple sclerosis (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IPX056 was compared with commercially available tablets as it was designed to provide a
      prolonged duration of absorption to reduce dose frequency and/or to provide prolonged
      duration of antispasticity effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning Stiffness Score</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Spasticity</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>IPX056-Baclofen IR-IPX056</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPX056-IPX056-Baclofen IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX056</intervention_name>
    <description>IPX056 ER capsule containing 10 mg baclofen</description>
    <arm_group_label>IPX056-Baclofen IR-IPX056</arm_group_label>
    <arm_group_label>IPX056-IPX056-Baclofen IR</arm_group_label>
    <other_name>IPX056 ER Capsule</other_name>
    <other_name>IPX056 ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen IR</intervention_name>
    <description>Encapsulated baclofen tablet 5 mg per capsule</description>
    <arm_group_label>IPX056-Baclofen IR-IPX056</arm_group_label>
    <arm_group_label>IPX056-IPX056-Baclofen IR</arm_group_label>
    <other_name>CAS Registry Number [11134-47-0]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IPX056</intervention_name>
    <description>Placebo capsule for IPX056</description>
    <arm_group_label>IPX056-Baclofen IR-IPX056</arm_group_label>
    <arm_group_label>IPX056-IPX056-Baclofen IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IR</intervention_name>
    <description>Placebo encapsulated baclofen placebo tablet</description>
    <arm_group_label>IPX056-Baclofen IR-IPX056</arm_group_label>
    <arm_group_label>IPX056-IPX056-Baclofen IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years old.

          -  Agrees to use a medically acceptable method of contraception throughout the study

          -  Diagnosed with MS as defined by Poser or McDonald Criteria.

          -  Receiving commercial baclofen tablets at a stable total daily dose ranging from 15 mg
             to 80 mg in a TID dosing regimen for at least 4 weeks prior to the Screening Visit
             that has resulted in improved spasticity.

          -  Willing to wash out and remain off other antispasticity medications during the study.

        Exclusion Criteria:

          -  If female, the subject is pregnant, planning to become pregnant, or breastfeeding.

          -  History of allergy or severe intolerance to baclofen.

          -  Did not respond to previous baclofen treatment in any formulation.

          -  Has experienced an exacerbation of MS within 1 month.

          -  Urinary tract infection (UTI) within 2 weeks or two symptomatic UTIs within 6 months
             prior to the study.

          -  Subjects with clinically significant impairment of renal function

          -  History of active seizure disorder or epilepsy, or currently taking an anticonvulsant
             for treatment or control of seizure.

          -  Other conditions causing spasticity (e.g., stroke, cerebral palsy, traumatic brain
             injury) or rigidity (e.g. Parkinson's Disease).

          -  Treated with Botulinum Toxin Type A or B within the previous 4 months, or with phenol
             or therapeutic alcohol nerve block within 12 months or planned use of these drugs
             during this study.

          -  Has clinically significant limitation of passive range of motion of lower extremities.

          -  Has had major surgery within 6 months prior to Screening Visit that may affect
             spasticity assessments such as abdominal surgery, back surgery, lower leg and knee
             surgeries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Impax Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Impax Laboratories (Impax Pharmaceuticals, a division of Impax Laboratories)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest NeuroSpecialists, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmerica Neuroscience Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Cllinic</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Neurology, PC</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <disposition_first_submitted>September 27, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 22, 2015</disposition_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

